Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
SCC-S2
/GG2-1/NDED is a recently discovered antiapoptotic molecule induced by the activation of the transcription factor NF-kappaB. Here we have examined a role of
SCC-S2
in cell growth regulation in vitro and in vivo. Western blotting using an antipeptide antibody revealed endogenous
SCC-S2
as a approximately 21 kDa cytosolic protein in human breast cancer cells (MDA-MB 231) and renal carcinoma cells (RCC-RS). The immunofluorescence detection method showed the cytosolic localization of FLAG-tagged human
SCC-S2
in COS-1 transfectants. MDA-MB 435 human cancer cells stably transfected with the FLAG-tagged
SCC-S2
cDNA exhibited increased growth rate as compared to control vector transfectants, as measured by the cell viability (>twofold; n=3; P<0.005) and thymidine-labeling procedures ( approximately sixfold; n=3; P<0.0001).
SCC-S2
transfectants also displayed an increase in cell migration in collagen I as compared to control transfectants ( approximately twofold; n=3; P<0.005). In athymic mice,
SCC-S2
transfectants showed significantly enhanced
tumor growth
as compared to control transfectants (mean tumor volumes, day 16: control, 56.86+/-19.82 mm(3);
SCC-S2
, 127.54+/-18.78 mm(3); n=5; P<0.03). The examination of a limited number of clinical specimens revealed higher expression levels of
SCC-S2
protein in certain human tumor tissues as compared to the matched normal adjacent tissues. Taken together, the present studies demonstrate
SCC-S2
as a novel oncogenic factor in cancer cells.
...
PMID:Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. 1472 90